Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31465294 | 1.00 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL30782446 | 1.00 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL2827679 | 1.00 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1812681 | 1.00 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL24327985 | 0.89 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL30782440 | 0.89 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL13618780 | 0.88 | SLC6A9 (0.60) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL2825210 | 0.87 | SLC6A9 (0.62) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL14683591 | 0.87 | SLC6A9 (0.51) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL2825561 | 0.87 | SLC6A9 (0.51) | SLC6A9SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577540-A1 | A SCALABLE PROCESS FOR THE PREPARATION OF A GLYT-1 INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| US-20240083889-A1 | Scalable process for the preparation of a GlyT-1 Inhibitor | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-03-14 | — | — | US | disclosed |
| WO-2024042043-A1 | A SCALABLE PROCESS FOR THE PREPARATION OF A GLYT-1 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| EP-2739615-B1 | PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2739615-B1 | PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| CN-104628679-A | New synthesis method and intermediate of Bitopertin | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2015-05-20 | — | — | CN | disclosed |
| CN-104628679-A | New synthesis method and intermediate of Bitopertin | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2015-05-20 | — | — | CN | disclosed |
| US-9012489-B2 | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012489-B2 | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012489-B2 | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| EP-1838308-A1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | SLC6A9 1024/4885SLC6A5 639/4885KCNH2 1197/4885 |
| US-20240083889-A1 | Scalable process for the preparation of a GlyT-1 Inhibitor | GLRA1, AGXT, GLRA3 | SLC6A9 28/4885SLC6A5 19/4885KCNH2 863/4885 |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | SLC6A9 23/4885SLC6A5 3/4885KCNH2 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.